我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
9
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
8
88.9%
终止
1
11.1%
暂无批准数据
- Kala Pharmaceuticals announced a safety update from Cohort 1 of its CHASE Phase 2b clinical trial, indicating progress in the ongoing study. - The company has successfully completed patient enrollment for the CHASE Phase 2 clinical trial, marking a significant milestone in the development program. - These developments represent important progress for Kala's clinical pipeline, though specific safety data and enrollment numbers were not disclosed in the available information.
